Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Health educators have duties to teach patient focus, motivate equity, and cultivate students’ capacity to serve our most vulnerable neighbors, wherever they reside.
AMA J Ethics. 2021;23(11):E858-863. doi:
10.1001/amajethics.2021.858.
Workplace wellness programs contribute to the wellness movement by enlisting nontraditional health partners and influencing social determinants of health.
AMA J Ethics. 2016;18(4):393-398. doi:
10.1001/journalofethics.2016.18.4.nlit1-1604.
This article considers that benefits of using humor in clinical settings come with risks of diminishing therapeutic capacity in patient-clinician relationships.
AMA J Ethics. 2020;22(7):E576-582. doi:
10.1001/amajethics.2020.576.